

OPIOIDS

Petros Levounis, MD, MA

Chair

Department of Psychiatry
Rutgers – New Jersey Medical School

Rutgers – New Jersey Medical School
Fundamentals of Addiction Medicine Summer Series
Newark, NJ – July 24, 2013

Outline

1. The Opioid Family
2. Intoxication and Withdrawal
3. Epidemiology
4. Pharmacological Treatments
5. Treating CNCP
6. Conclusions

1

The Opioid Family

The Opium Poppy



Morphine circa 1887

MRS WINSLOW'S


THE
MOTHER'S
FRIEND




FOR
CHILDREN
TEETHING

SOOTHING SYRUP

Morphine



Di-Acetyl-Morphine (Heroin)



Types of Opioid Receptors

1. Mu
2. Kappa
3. Delta

Opioid Medications

1. Naturally Occurring Opioids

Morphine

Codeine

2. Semi-Synthetic Opioids

Oxymorphone

Oxycodone

Hydromorphone

Hydrocodone

3. Synthetic Opioids

Fentanyl

(Tramadol)

Methadone

Buprenorphine

Opioid Effects

1. Relief of physical pain
2. Relief of emotional pain
3. Euphoria
4. Decreased anxiety, calmness
5. Cough suppression

2

Intoxication and Withdrawal

Opioid Intoxication

1. Constricted pupils
2. Constipation
3. Nausea and vomiting (often projectile)
4. Respiratory depression
5. Coma and death


Opioid Withdrawal

1. Dilated pupils
2. Diarrhea
3. Flu-like symptoms (rhinorrhea, lacrimation)
4. Yawning
5. Unbearable body aches
6. Sweats and piloerection (“cold turkey”)


3

Epidemiology

Heroin Admissions




Non-Heroin Opioid Admissions




Admissions: 1999

Primary non-heroin opioid admission rates (per 100,000)




Admissions: 2001

Primary non-heroin opioid admission rates (per 100,000)




Admissions: 2003

Primary non-heroin opioid admission rates (per 100,000)




Admissions: 2005

Primary non-heroin opioid admission rates (per 100,000)



Admissions: 2007


Primary non-heroin opioid admission rates (per 100,000)



< 8		15 - 18		45 or more		SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS). Data received through 11.03.10.
8 - 14		19 - 44		Incomplete data		

Admissions: 2009


Primary non-heroin opioid admission rates (per 100,000)



< 8		15 - 18		45 or more		SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS). Data received through 11.03.10.
8 - 14		19 - 44		Incomplete data		

1998, United States

Unintentional Injuries and Adverse Effects
 Ages 19–50, White, Non–Hispanic*, Both Sexes
 Total Deaths: 29,600



NEC means Not Elsewhere Classifiable.


WISQARS™ Produced by: Office of Statistics and Programming, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention
 Data Source: National Center for Health Statistics (NCHS), National Vital Statistics System

2000, United States

Unintentional Injuries

Ages 19–50, White, Non–Hispanic, Both Sexes

Total Deaths: 30,661




NEC means Not Elsewhere Classifiable.

2002, United States

Unintentional Injuries

Ages 19–50, White, Non–Hispanic, Both Sexes

Total Deaths: 34,469



NEC means Not Elsewhere Classifiable.


WISQARS™ Produced by: Office of Statistics and Programming, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention
 Data Source: National Center for Health Statistics (NCHS), National Vital Statistics System

2004, United States

Unintentional Injuries

Ages 19–50, White, Non–Hispanic, Both Sexes

Total Deaths: 36,303



NEC means Not Elsewhere Classifiable.

WISQARS™

Produced by: Office of Statistics and Programming, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention


Data Source: National Center for Health Statistics (NCHS), National Vital Statistics System

2006, United States

Unintentional Injuries

Ages 19–50, White, Non–Hispanic, Both Sexes

Total Deaths: 39,971



NEC means Not Elsewhere Classifiable.


WISQARS™ Produced by: Office of Statistics and Programming, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention
 Data Source: National Center for Health Statistics (NCHS), National Vital Statistics System

2008, United States

Unintentional Injuries

Ages 19–50, White, Non–Hispanic, Both Sexes

Total Deaths: 39,081




NEC means Not Elsewhere Classifiable.

WISQARS™


Produced by: Office of Statistics and Programming, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention

Data Source: National Center for Health Statistics (NCHS), National Vital Statistics System

Unintentional Drug Overdose Deaths United States: 1970–2007




Prescription Opioids 1999-2010



SOURCES: National Vital Statistics System, 1999-2008; Automation of Reports and Consolidated Orders System (ARCOS) of the Drug Enforcement Administration (DEA), 1999-2010; Treatment Episode Data Set, 1999-2009

Prescription Opioids 2012



The Prescription Opioids Epidemic: The Root of the Disaster

ADDICTION RARE IN PATIENTS TREATED WITH NARCOTICS

To the Editor: We examined 1,000 files to determine the incidence of narcotic addiction in 16 hospitalized medical patients who were monitored intensively. Although there were 11,882 prescriptions for one narcotic preparation, there were only 16 cases of addiction. The addiction was considered major in 12 patients and minor in 4. The drugs implicated were meperidine in 12, Percodan in one, and hydromorphone in one. We conclude that despite widespread use of narcotic drugs in hospitals, addiction is rare in hospitalized medical patients with narcotic addiction.

JANE PORTER

MARSHEL JICK, M.D.

Collaborative Drug

Abuse Surveillance Program

Waltham, MA

Boston University Medical Center

1. Jick H, et al, Shapiro S, Lewis C, et al, Slone D. Comprehensive drug surveillance. JAMA. 1976; 236:1000-1004.
2. Miller RR, Jick H. Clinical effects of meperidine in hospitalized medical patients. J Clin Pharmacol. 1978; 18:180-8.

Pharma

FREEDOM FROM PAIN!

Extra strength pain relief
free of extra sedating
restrictions

- Telephone prescribing
- Up to five refills in 6 months
- No triplicate Rx required

Excellent patient acceptance.

In 12 years of clinical experience, nausea, sedation, and constipation have rarely been reported.¹

COMPARATIVE PHARMACOLOGY OF TWO		
	Constipation	Respiratory Depression
HYDROCODONE		X
OXYCODONE	XX	XX

Blank space indicates that no such activity has been reported. ¹Ann. Intern. Med. 1991; 115: 1000-1001. ²Ann. Intern. Med. 1975; 82: 379-92 and Reuler JB, et. al. The chronic pain patient. ³Ann. Intern. Med. 1990; 112: 988-96.

The heritage of VICODIN ES doses prescribed

- VICODIN ES provides analgesic action than other hydrocodone combinations.
- Four to six hours of relief from a single dose
- The 14th most frequently prescribed pain medication in America²

vicodin ES 

(hydrocodone bitartrate 7.5mg/paracetamol 650mg) Immediate Release Tablets

4

Pharmacological Treatments

Three Options

- Agonist: Methadone
- Partial Agonist: Buprenorphine
- Antagonist: Naltrexone

Full Agonist Effects

**Mu
receptor**

Full agonist binding ...

- ① activates the mu receptor
- ② is highly reinforcing
- ③ is the most abused opioid type
- ④ includes heroin, codeine, & others

Antagonist Effects



- ① occupies without activating
- ② is not reinforcing
- ③ blocks abused agonist opioid types
- ④ includes naloxone and naltrexone

Partial Agonist Effects


**Mu
receptor**

Partial agonist binding ...

- ① activates the receptor at lower levels
- ② is relatively less reinforcing
- ③ is a less abused opioid type
- ④ includes buprenorphine

Precipitated Withdrawal


- Buprenorphine will precipitate withdrawal only when it displaces a full agonist off the mu receptors.
- Buprenorphine only partially activates the receptors, therefore a net decrease in activation occurs and withdrawal develops.



Discrepancy Between Populations Abusing Opioids & Population Treated

Opioid Abuse


NSDUH Past Month Use 2002



4,549,570 reported opioid abuse

Methadone Treatment


TEDS 2002 Admissions Involving Methadone Treatment



111,885 admissions involved methadone treatment

Treatment Under the Waiver (BUP)

Patient Study BUP Evaluation 2005




434 patients recruited from 132 sites

■ Heroin Only


■ Non-heroin Opioids Only

■ Heroin & Non-heroin Opioids

Neonatal Abstinence Syndrome



Maintenance v. Detoxification 1



Maintenance v. Detoxification 2

	Detox/Placebo	Buprenorphine	Cox regression
Dead	4/20 (20%)	0/20 (0%)	$\chi^2=5.9$; $p=0.015$

5

Treating Chronic Non-Cancer Pain

Non-Opioid Strategies

1. NSAIDs and acetaminophen
2. Corticosteroids
3. Anticonvulsants and antidepressants
4. Capsaicin for neuropathic pain
5. Transdermal lidocaine
6. Physical Therapy
7. Exercise and Relaxation Techniques
8. Cognitive Behavioral Therapy

Chronic Opioid Therapy

Opioids are not first-line treatments for chronic non-cancer pain.

Three major problems:

1. Lack of Efficacy
2. Significant Health Risks
3. Addiction

Lack of Efficacy

- Evidence of long-term efficacy for chronic non-cancer pain (>16 weeks) is limited and of low quality.
- For many patients with chronic pain, analgesic efficacy is not maintained over long time periods.

Significant Health Risks

- Fractures from falls (especially for patients over 60)
- Fatal unintentional overdose from respiratory depression
- Hyperalgesia
- Sexual dysfunction
- Hypogonadism
- Chronic constipation and fecal impaction
- Chronic dry mouth and tooth decay
- Dry skin and pruritus

The 2009 Article

- American Pain Society and American Academy of Pain Medicine multi-disciplinary expert panel
- Chronic Opioid Therapy (COT) in Chronic Noncancer Pain (CNCP)
- 14 Areas of Concern
- 25 Recommendations
 - 21 “Low-quality evidence”
 - 4 “Moderate-quality evidence”

1. Opioid Risk Tool

		Mark each box that applies	Item score if female	Item score if male
1. Family history of substance abuse	<ul style="list-style-type: none"> • Alcohol • Illegal drugs • Prescription drugs 	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	1 2 4	3 3 4
2. Personal history of substance abuse	<ul style="list-style-type: none"> • Alcohol • Illegal drugs • Prescription drugs 	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	3 4 5	3 4 5
3. Age (mark box if 16-45)		<input type="checkbox"/>	1	1
4. History of preadolescent sexual abuse		<input type="checkbox"/>	3	0
5. Psychological disease	<ul style="list-style-type: none"> • Attention-deficit disorder, obsessive-compulsive disorder, bipolar disorder, schizophrenia 	<input type="checkbox"/>	2	2
	<ul style="list-style-type: none"> • Depression 	<input type="checkbox"/>	1	1

Total Score _____ Risk Category _____

Low Risk: 0 to 3

Moderate Risk: 4 to 7

High Risk: 8 and above

Source: Webster LR, Webster R. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. *Pain Med.* 2005;6(6):432.

2. Morphine Equianalgesic Doses

1. Naturally Occurring Opioids

Morphine	30
Codeine	200

2. Semi-Synthetic Opioids

Oxymorphone	10
Oxycodone	20
Hydromorphone	7.5
Hydrocodone	30

For MED over 100 per day, reassess!

3. Depression

- ✓ Depression often manifests as physical pain, indistinguishable to the patient from somatic pain
- ✓ Assessment focuses on accompanying symptoms of:
 - Loss of pleasure
 - Loss of energy
 - Sadness
 - Appetite and sleep disturbances
 - Guilt and thoughts of death


4. Urine Toxicology Exams



Use of which one of the following can turn a Urine Toxicology Examination positive for both codeine and morphine?

- A. Heroin
- B. Hydrocodone
- C. Oxycodone
- D. Poppy seed bagels
- E. All of the above

Opioid Metabolism



Urine Toxicology Detection Limits

❖ Alcohol	7-12 hours
❖ Alcohol (Ethyl glucuronide, EtG test)	4 days
❖ Amphetamines/Methamphetamines	2 days
❖ Benzodiazepines (Short-acting)	3 days
❖ Benzodiazepines (Long-acting)	30 days
❖ Cocaine	2-4 days
❖ Heroin (Morphine)	2 days
❖ Methadone	3 days
❖ Marijuana (Single use)	3 days
❖ Marijuana (Long-term heavy use)	>30 days

5. Acetaminophen Warning

Hepatotoxicity can result from prolonged use of combination opioid/acetaminophen products.

- Short-term use (<10 days) – 4,000 mg/day
- Long-term use – 2,500 mg/day

And One More ...



An opioid dependent patient has decided to undertake an opioid discontinuation trial. She asks for specific advice while she is still taking opioids.

All of the following are good recommendations, EXCEPT:

- A. Fill your prescriptions at one pharmacy
- B. Keep medications in a secure location, preferably locked.
- C. Avoid alcohol, benzodiazepines, muscle relaxants, and monoamine oxidase inhibitors (MAOIs)
- D. Discard unused medication down the toilet
- E. All of the above are excellent recommendations!

6

Conclusions

1. Opioids relieve physical and emotional pain by activating the μ opioid receptor.
2. Prescription opioid use has now become a nation-wide epidemic.
3. Opioids have been shown to be neither effective nor safe in the treatment of chronic non-cancer pain.
4. In 2013, buprenorphine maintenance is the first line pharmacological treatment of opioid addiction.

Thank you